Squarepoint Ops LLC Crispr Therapeutics Ag Call Options Transaction History

Squarepoint Ops LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $214,914 - $286,356	-4,200 Reduced 26.25%	11,800 $637,000
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $188,077 - $276,272	-3,100 Reduced 16.23%	16,000 $1.09 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $351,442 - $656,838	9,100 Added 91.0%	19,100 $1.2 Million
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $43,470 - $67,770	-1,000 Reduced 9.09%	10,000 $561,000
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $848,700 - $1.16 Million	-20,700 Reduced 65.3%	11,000 $497,000
Q4 2022 Feb 14, 2023	SELL	$39.19 - $65.67 $11,757 - $19,701	-300 Reduced 0.94%	31,700 $1.29 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $1.96 Million - $2.68 Million	32,000 New	32,000 $2.09 Million

503

57M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.03B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.